212 related articles for article (PubMed ID: 21748755)
1. Lenalidomide modulates IL-8 and anti-prostate antibody levels in men with biochemically recurrent prostate cancer.
Zabransky DJ; Smith HA; Thoburn CJ; Zahurak M; Keizman D; Carducci M; Eisenberger MA; McNeel DG; Drake CG; Antonarakis ES
Prostate; 2012 Apr; 72(5):487-98. PubMed ID: 21748755
[TBL] [Abstract][Full Text] [Related]
2. Lenalidomide in nonmetastatic biochemically relapsed prostate cancer: results of a phase I/II double-blinded, randomized study.
Keizman D; Zahurak M; Sinibaldi V; Carducci M; Denmeade S; Drake C; Pili R; Antonarakis ES; Hudock S; Eisenberger M
Clin Cancer Res; 2010 Nov; 16(21):5269-76. PubMed ID: 20978144
[TBL] [Abstract][Full Text] [Related]
3. Association between immunosuppressive cytokines and PSA progression in biochemically recurrent prostate cancer treated with intermittent hormonal therapy.
Hawley JE; Pan S; Figg WD; Lopez-Bujanda ZA; Strope JD; Aggen DH; Dallos MC; Lim EA; Stein MN; Hu J; Drake CG
Prostate; 2020 Mar; 80(4):336-344. PubMed ID: 31899823
[TBL] [Abstract][Full Text] [Related]
4. Is undetectable prostate-specific antigen always reliable to rule out prostate cancer recurrence after radical prostatectomy?
Schriefer P; Steurer S; Huland H; Graefen M
J Clin Oncol; 2012 Nov; 30(32):e341-4. PubMed ID: 23032622
[No Abstract] [Full Text] [Related]
5. Sargramostim (GM-CSF) and lenalidomide in castration-resistant prostate cancer (CRPC): results from a phase I-II clinical trial.
Garcia JA; Elson P; Tyler A; Triozzi P; Dreicer R
Urol Oncol; 2014 Jan; 32(1):33.e11-7. PubMed ID: 23510862
[TBL] [Abstract][Full Text] [Related]
6. Role of Epigenetic Modification and Immunomodulation in a Murine Prostate Cancer Model.
Sulek JE; Robinson SP; Petrossian AA; Zhou S; Goliadze E; Manjili MH; Toor A; Guruli G
Prostate; 2017 Mar; 77(4):361-373. PubMed ID: 27862100
[TBL] [Abstract][Full Text] [Related]
7. CD8
Shore ND; Morrow MP; McMullan T; Kraynyak KA; Sylvester A; Bhatt K; Cheung J; Boyer JD; Liu L; Sacchetta B; Rosencranz S; Heath EI; Nordquist L; Cheng HH; Tagawa ST; Appleman LJ; Tutrone R; Garcia JA; Whang YE; Kelly WK; Weiner DB; Bagarazzi ML; Skolnik JM
Mol Ther; 2020 May; 28(5):1238-1250. PubMed ID: 32208168
[TBL] [Abstract][Full Text] [Related]
8. Current status of thalidomide and CC-5013 in the treatment of metastatic prostate cancer.
Sissung TM; Thordardottir S; Gardner ER; Figg WD
Anticancer Agents Med Chem; 2009 Dec; 9(10):1058-69. PubMed ID: 19719457
[TBL] [Abstract][Full Text] [Related]
9. Antigen-presenting cells 8015 (Provenge) in patients with androgen-dependent, biochemically relapsed prostate cancer.
Beinart G; Rini BI; Weinberg V; Small EJ
Clin Prostate Cancer; 2005 Jun; 4(1):55-60. PubMed ID: 15992463
[TBL] [Abstract][Full Text] [Related]
10. MR imaging evaluation with a transrectal surface coil of local recurrence of prostatic cancer in men who have undergone radical prostatectomy.
Silverman JM; Krebs TL
AJR Am J Roentgenol; 1997 Feb; 168(2):379-85. PubMed ID: 9016212
[TBL] [Abstract][Full Text] [Related]
11. Final report of a phase 2 clinical trial of lenalidomide monotherapy for patients with T-cell lymphoma.
Toumishey E; Prasad A; Dueck G; Chua N; Finch D; Johnston J; van der Jagt R; Stewart D; White D; Belch A; Reiman T
Cancer; 2015 Mar; 121(5):716-23. PubMed ID: 25355245
[TBL] [Abstract][Full Text] [Related]
12. Mitoxantrone in patients with prostate specific antigen progression after local therapy for prostate carcinoma.
DiPaola RS; Chenven ES; Shih WJ; Lin Y; Amenta P; Goodin S; Shumate A; Capanna T; Cardiella M; Cummings KB; Aisner J; Todd MB
Cancer; 2001 Oct; 92(8):2065-71. PubMed ID: 11596021
[TBL] [Abstract][Full Text] [Related]
13. Change in PSA velocity is a predictor of overall survival in men with biochemically-recurrent prostate cancer treated with nonhormonal agents: combined analysis of four phase-2 trials.
Suzman DL; Zhou XC; Zahurak ML; Lin J; Antonarakis ES
Prostate Cancer Prostatic Dis; 2015 Mar; 18(1):49-55. PubMed ID: 25384338
[TBL] [Abstract][Full Text] [Related]
14. False elevations in prostate-specific antigen levels affecting patient management.
Kummar S; Shafi NQ
Clin Adv Hematol Oncol; 2004 Sep; 2(9):599-601; discussion 602. PubMed ID: 16163243
[No Abstract] [Full Text] [Related]
15. Changes in PSA kinetics predict metastasis- free survival in men with PSA-recurrent prostate cancer treated with nonhormonal agents: combined analysis of 4 phase II trials.
Antonarakis ES; Zahurak ML; Lin J; Keizman D; Carducci MA; Eisenberger MA
Cancer; 2012 Mar; 118(6):1533-42. PubMed ID: 21960118
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of the human anti-epithelial cell adhesion molecule antibody adecatumumab in prostate cancer patients with increasing serum levels of prostate-specific antigen after radical prostatectomy.
Marschner N; Rüttinger D; Zugmaier G; Nemere G; Lehmann J; Obrist P; Baeuerle PA; Wolf A; Schmidt M; Abrahamsson PA; Reinhardt C; Heidenreich A
Urol Int; 2010; 85(4):386-95. PubMed ID: 20606402
[TBL] [Abstract][Full Text] [Related]
17. Lenalidomide monotherapy in chemotherapy-naive, castration-resistant prostate cancer patients: final results of a phase II study.
Nabhan C; Patel A; Villines D; Tolzien K; Kelby SK; Lestingi TM
Clin Genitourin Cancer; 2014 Feb; 12(1):27-32. PubMed ID: 24238760
[TBL] [Abstract][Full Text] [Related]
18. Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial.
Trněný M; Lamy T; Walewski J; Belada D; Mayer J; Radford J; Jurczak W; Morschhauser F; Alexeeva J; Rule S; Afanasyev B; Kaplanov K; Thyss A; Kuzmin A; Voloshin S; Kuliczkowski K; Giza A; Milpied N; Stelitano C; Marks R; Trümper L; Biyukov T; Patturajan M; Bravo MC; Arcaini L;
Lancet Oncol; 2016 Mar; 17(3):319-331. PubMed ID: 26899778
[TBL] [Abstract][Full Text] [Related]
19. Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer.
Drachenberg DE; Elgamal AA; Rowbotham R; Peterson M; Murphy GP
Prostate; 1999 Oct; 41(2):127-33. PubMed ID: 10477909
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the percent free prostate-specific antigen levels in the serum of healthy men and in men with recurrent prostate cancer after radical prostatectomy.
Scorilas A; Yu H; Soosaipillai AR; Gregorakis AK; Diamandis EP
Clin Chim Acta; 2000 Feb; 292(1-2):127-38. PubMed ID: 10686282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
